Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.

Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R.

Sci Rep. 2016 Sep 13;6:32992. doi: 10.1038/srep32992.

2.

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.

Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY.

Cancer Lett. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Epub 2016 Jul 19.

PMID:
27450722
3.

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.

Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R.

Oncotarget. 2017 Mar 21;8(12):18726-18734. doi: 10.18632/oncotarget.9640.

4.

Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.

Lennon FE, Cianci GC, Kanteti R, Riehm JJ, Arif Q, Poroyko VA, Lupovitch E, Vigneswaran W, Husain A, Chen P, Liao JK, Sattler M, Kindler HL, Salgia R.

Sci Rep. 2016 Apr 15;6:24578. doi: 10.1038/srep24578.

5.

FAK and paxillin, two potential targets in pancreatic cancer.

Kanteti R, Batra SK, Lennon FE, Salgia R.

Oncotarget. 2016 May 24;7(21):31586-601. doi: 10.18632/oncotarget.8040. Review.

6.

C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.

Kanteti R, Dhanasingh I, El-Hashani E, Riehm JJ, Stricker T, Nagy S, Zaborin A, Zaborina O, Biron D, Alverdy JC, Im HK, Siddiqui S, Padilla PA, Salgia R.

Cancer Biol Ther. 2016;17(1):91-103. doi: 10.1080/15384047.2015.1108495.

PMID:
26574927
7.

Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy.

Allen MJ, Kanteti R, Riehm JJ, El-Hashani E, Salgia R.

Nanomedicine. 2015 Nov;11(8):1971-4. doi: 10.1016/j.nano.2015.07.014. Epub 2015 Aug 15.

8.

Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.

Ferguson BD, Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, Iafrate AJ, Gill PS, Salgia R.

Sci Rep. 2015 Jun 15;5:10641. doi: 10.1038/srep10641.

9.

MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.

Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R.

PLoS One. 2014 Sep 15;9(9):e105919. doi: 10.1371/journal.pone.0105919. eCollection 2014.

10.

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.

Kanteti R, El-Hashani E, Dhanasingh I, Tretiakova M, Husain AN, Sharma S, Sharma J, Vokes EE, Salgia R.

BMC Cancer. 2014 Mar 14;14:185. doi: 10.1186/1471-2407-14-185.

11.

Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R.

Mol Cancer Ther. 2014 Mar;13(3):576-84. doi: 10.1158/1535-7163.MCT-13-0109. Epub 2013 Dec 10.

12.

O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer.

Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R.

J Carcinog. 2013 Oct 28;12:20. doi: 10.4103/1477-3163.120632. eCollection 2013.

13.

The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.

Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia R.

PLoS One. 2013 Jul 2;8(7):e67668. doi: 10.1371/journal.pone.0067668. Print 2013.

14.

Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.

Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR.

J Clin Oncol. 2013 Jun 1;31(16):e254-8. doi: 10.1200/JCO.2012.46.4289. Epub 2013 Apr 22. No abstract available.

15.

Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.

Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R.

Cancer Res. 2013 Jan 1;73(1):184-94. doi: 10.1158/0008-5472.CAN-12-0915. Epub 2012 Oct 24. Erratum in: Cancer Res. 2013 Jul 15;73(14):4594.

16.

Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.

Kalari S, Moolky N, Pendyala S, Berdyshev EV, Rolle C, Kanteti R, Kanteti A, Ma W, He D, Husain AN, Kindler HL, Kanteti P, Salgia R, Natarajan V.

PLoS One. 2012;7(9):e45330. doi: 10.1371/journal.pone.0045330. Epub 2012 Sep 17.

17.

The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization.

Lo FY, Chang JW, Chang IS, Chen YJ, Hsu HS, Huang SF, Tsai FY, Jiang SS, Kanteti R, Nandi S, Salgia R, Wang YC.

BMC Cancer. 2012 Jun 12;12:235. doi: 10.1186/1471-2407-12-235.

18.

Differential expression of RON in small and non-small cell lung cancers.

Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R.

Genes Chromosomes Cancer. 2012 Sep;51(9):841-51. doi: 10.1002/gcc.21968. Epub 2012 May 14.

PMID:
22585712
19.

Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.

Do├ži CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R, Lingen MW.

Int J Gynecol Pathol. 2012 Jan;31(1):15-24. doi: 10.1097/PGP.0b013e318220ba16.

20.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.

Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia R.

J Clin Bioinforma. 2011 Feb 28;1(8):1-11. doi: 10.1186/2043-9113-1-8.

Supplemental Content

Loading ...
Support Center